@article{Tinto2014-hc,

title = {Effectiveness of artesunate-amodiaquine vs. 

 artemether-lumefantrine for the treatment of uncomplicated 

 falciparum malaria in Nanoro, Burkina Faso: a non-inferiority 

 randomised trial},

author = {Halidou Tinto and Salou Diallo and Issaka Zongo and Issa Guiraud and Innocent Valea and Adama Kazienga and Herv\'{e} Kpoda and Hermann Sorgho and Jean-Bosco Ou\'{e}draogo and Tinga Robert Guiguemd\'{e} and Umberto D'Alessandro},

year  = {2014},

date = {2014-04-01},

journal = {Trop. Med. Int. Health},

volume = {19},

number = {4},

pages = {469--475},

publisher = {Wiley},

abstract = {OBJECTIVES: Artemisinin-based combination therapies (ACTs) are 

 essential for the effective control of falciparum malaria in 

 endemic countries. However, in most countries, such choice has 

 been carried out without knowing their effectiveness when 

 deployed in real-life conditions, that is, when treatment is not 

 directly observed. We report here the results of a study 

 assessing the effectiveness of the two ACTs currently 

 recommended in Burkina Faso for the treatment of uncomplicated 

 malaria, that is, artemether-lumefantrine (AL) and 

 artesunate-amodiaquine (ASAQ). METHODS: Between September 2008 

 and January 2010, 340 children were randomised to one of the two 

 study arms and followed up for 42 days. Treatment was 

 administered according to routine practices, that is, the first 

 dose was given by study nurses who explained to the 

 parent/guardian how to administer the other doses at home during 

 the following 2 days. RESULTS: The results showed a 

 significantly higher unadjusted adequate clinical and 

 parasitological response in the ASAQ (58.4%) than in the AL arm 

 (46.1%) at day 28 but these trends were similar after 

 correction with PCR data (ASAQ (89.7%) and AL (89.8%)). New 

 infections started to appear after day 14, first in the AL and 

 then in the ASAQ arm but at day 42 day of follow-up we observed 

 no difference in the occurrence of recrudescent infection. 

 CONCLUSION: Despite a lower cure rate than those reported in 

 efficacy studies in which the treatment administration was 

 directly observed, both AL and ASAQ can still be used for the 

 treatment of uncomplicated malaria in Burkina Faso.},

keywords = {Burkina Faso; artemisinin-based combination therapies;   effectiveness; uncomplicated malaria},

pubstate = {published},

tppubtype = {article}

}